Company: ARTL
Filing Date: 2025-09-05
Form Type: 424B5
Source: 0001640334-25-001629
Chunk: 49

Company: ARTELO BIOSCIENCES, INC.
Filing Date: 2025-09-05
Form: 424B5
Chunk 49
---
 date of this prospectus, actual results may differ from the projections.

<div align='center'>USE OF PROCEEDS</div>

We will retain broad discretion over the use of the net proceeds to us from the sale of our securities under this prospectus. Unless otherwise provided in the applicable prospectus supplement, we currently expect to use the net proceeds that we receive from this offering for working capital and other general corporate purposes. We may also use a portion of the net proceeds to acquire, license or invest in complementary products, technologies or businesses; however, we currently have no agreements or commitments to complete any such transaction. The expected use of net proceeds of this offering represents our current intentions based on our present plans and business conditions. We cannot specify with certainty all of the particular uses for the net proceeds to be received upon the closing of this offering. Pending these uses, we plan to invest the net proceeds of this offering in short- and intermediate-term, interest-bearing obligations, investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government.

| 9 |

<div align='center'>DESCRIPTION OF CAPITAL STOCK</div>

The description of our capital stock is incorporated by reference from Exhibit 4.1 to our Annual Report on Form 10‑K for the fiscal year ended December 31, 2022 filed with the SEC on March 31, 2023.

<div align='center'>DESCRIPTION OF DEBT SECURITIES</div>

The following description, together with the additional information we include in any applicable prospectus supplement, summarizes certain general terms and provisions of the debt securities that we may offer under this prospectus. When we offer to sell a particular series of debt securities, we will describe the specific terms of the series in a supplement to this prospectus. We will also indicate in the supplement to what extent the general terms and provisions described in this prospectus apply to a particular series of debt securities.

We may issue debt securities either separately, or together with, or upon the conversion or exercise of or in exchange for, other securities described in this prospectus. Debt securities may be our senior, senior subordinated or subordinated obligations and, unless otherwise specified in a supplement to this prospectus, the debt securities will be our direct, unsecured obligations and may be issued in one or more series.

The debt securities will be issued under an indenture between us and a trustee to be identified in an accompanying prospectus supplement. We have summarized select portions of the indenture below. The summary is not complete